Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: Long-term study

Retina

Volumn 26, Issue 7, 2006, Pages 746-751

  Pece, Alfredo ^a   Isola, Vincenzo ^a   Vadalà, Maria ^b   Matranga, Domenica ^b  

^a Melegnano Hospital   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Myopia; Photodynamic therapy; Subfoveal choroidal neovascularization; Verteporfin

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ADULT; AGED; AGING; ARTICLE; CLINICAL EXAMINATION; DETERIORATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOPIA; PATIENT SAFETY; PHOTODYNAMIC THERAPY; PROGNOSIS; REFRACTION ERROR; SLIT LAMP; SUBRETINAL NEOVASCULARIZATION; VISION; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 33748643809     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iae.0000244256.60524.c0     Document Type: Article

References (26)

1. Sperduto RD, Seigel D, Roberts J, Rowland M. Prevalence of myopia in the United States. Arch Ophthalmol 1983;101:405-407.
2. Hampton RG, Kohen D, Bird AC, et al. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983;90:923-926.
3. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol 1983;67:209-213.
4. Curtin BJ, Karlin DB. Axial length measurements and fundus changes of the myopic eye. Am J Ophthalmol 1971;1:42-53.
5. Grossniklauss HE, Green WG. Pathologic findings in pathologic myopia. Retina 1992;12:127-133.
6. Soubrane G, Coscas G. Choroidal neovascular membranes in degenerative myopia. In: Ryan SJ, ed. Retina. St. Louis, MO: Mosby-Year Book; 1994:1143-1157.
7. Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 1981;91:177-183.
8. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983;90:923-926.
9. Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-1581.
10. Tabandeh H, Flynn HW, Scott IU, et al. Visual acuity outcome of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999;106:2063-2067.
11. Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia. A comparison between age groups. Ophthalmology 2002;109:712-719.
12. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization. A 10-year follow-up. Ophthalmology 2003;110:1297-1305.
13. Soubrane G, Pison J, Bornert P, et al. Néovaisseaux sousrétiniens de la myopie dégénérative: résultats de la photocoagulation. Bull Soc Ophtalmol Fr 1986;86:296-272.
14. Pece A, Menchini U, Serini P, Brancato R. Green argon laser versus red krypton and dye laser (590nm) in the treatment of myopic macular degeneration. In: Brancato R, Coscas G, Lumbroso B, eds. Retinal Diseases - 2. Amsterdam: Kugler & Ghedini; 1987:49-51.
15. Pece A, Brancato R, Avanza P, et al. Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results. Int Ophthalmol 1995;18:339-344.
16. Secretan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia. Natural history and laser treatment. Eur J Ophthalmol 1997;7:307-316.
17. Jalkh AE, Weiter JJ, Trempe CL, et al. Choroidal neovascularization in degenerative myopia: role of laser photocoagulation. Ophthalmic Surg 1987;18:721-725.
18. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, and Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002;22:6-18.
19. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-years results of a randomized clinical trial - VIP report no 3. Ophthalmology 2003;110:667-673.
20. Pérez Oliván S, Torrón Fernández-Blanco C, Ferrer Novella E, et al. Terapia fotodinámica en neovascularizació n coroidea. Arch Soc Esp Oftalmol 2004;79:609-616.
21. Lam DSC, Chan W-M, Liu DT, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow-up. Br J Ophthalmol 2004;88:1315-1319.
22. Ergun E, Heinzl H, Stur M. Prognostic factor influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 2004;138:434-438.
23. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularization. Br J Ophthalmol 2003;87:173-176.
24. Axer-Siegel R, Ehrlich R, Weinberger D, et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 2004;138:602-607.
25. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is the major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000;41:3158-3164.
26. Azab M, Boyer DS, Bressler NM, et al. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-457.